Addex to Present at the Swiss Biotech Day 2022
Geneva, Switzerland, April 28, 2022 – Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical…
Geneva, Switzerland, April 28, 2022 – Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical…
April 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology…
PETALING JAYA, Malaysia, Apr 28, 2022 – (ACN Newswire) – Malaysian Genomics Resource Centre Berhad…
AUSTIN, Texas–(BUSINESS WIRE)–Fundamental Labs, a blockchain and digital asset focused venture capital firm, has announced…
The company will demonstrate its edge AI accelerator and software technologies at the upcoming Embedded…
ADSCC and Dante Labs sign agreement Dr. Yendry Ventura Carmenate, General Manager at Abu Dhabi…
In a press release issued earlier today by Affimed N.V. (Nasdaq: AFMD), please note that…
-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University…
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company…
ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained…
FORT COLLINS, Colo., April 27, 2022 (GLOBE NEWSWIRE) — Statera Biopharma (Nasdaq: STAB) (the “Company”),…
SINGAPORE, April 27, 2022 (GLOBE NEWSWIRE) — Genius Group (NYSE American: GNS) is pleased to…
ANDOVER, Mass., April 27, 2022 (GLOBE NEWSWIRE) — Mercury Systems Inc. (NASDAQ: MRCY, www.mrcy.com), a…
Jakarta, Indonesia–(Newsfile Corp. – April 27, 2022) – After a successful partnership with Danamas –…
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm,…
Revenue from Continuing Operations Increased 37.8% PLANO, Texas–(BUSINESS WIRE)–BGSF, Inc. (NYSE: BGSF), a leading national…
Nomination for Dr. Sadat showcases Retrace’s commitment to improve the entire dental landscape by using…
Q1 2022 Net Income of $74.9 million, or $2.18 Per Diluted Share, Up 126% Over…
Net Income of $59.3 Million and Earnings Per Share of $5.75 Petroleum Additives Operating Profit…